PU.1激活的基因组区域定义以免疫失调和疾病进展为特征的低危MDS亚群
该研究对86例和357例患者CD34+骨髓祖细胞分别进行H3K27ac ChIP-seq和RNA-seq,分析MDS疾病进展的基因组相关因素。无监督聚类发现一个低危MDS亚群,其调控和转录谱类似高危MDS和sAML,以PU.1占据免疫炎症相关区域、T细胞和NK细胞活化增加及SRSF2突变频率较高为特征,临床感染和心血管事件易感、进展风险高、总生存显著降低。功能研究显示抑制PU.1可抑制MDS细胞增殖和克隆形成。
要点
- 低危MDS中存在调控转录谱类似高危MDS/sAML的亚群,提示早期分子事件 predispose 疾病进展。
- 该亚群以PU.1占据免疫炎症相关基因组区域、T/NK细胞活化增加和SRSF2突变频率较高为特征。
- 该亚群临床感染和心血管事件易感、疾病进展风险升高、总生存显著降低。
核心结论
- 研究发现表观遗传因素使部分低危MDS患者易进展为高危MDS并最终进展为sAML。
研究设计与样本
- 对前瞻性队列中86例患者CD34+骨髓祖细胞进行H3K27ac ChIP-seq分析。
- 对357例患者CD34+骨髓祖细胞进行RNA-seq分析。
主要发现
- 无监督聚类发现一个低危MDS亚群,其调控和转录谱与高危MDS和sAML相似。
- 该亚群以PU.1占据免疫和炎症反应相关区域、T细胞和自然杀伤细胞活化增加及SRSF2突变频率较高为特征。
- 该亚群患者感染和心血管事件易感性更高,疾病进展风险升高,总生存显著降低。
- 功能研究显示抑制PU.1可抑制MDS细胞增殖和克隆形成,PU.1结合受损可抑制疾病进展相关关键转录程序的激活。
临床怎么用
- 对低危MDS患者可关注PU.1相关表观遗传特征以识别进展高风险亚群。
- 该亚群患者需警惕感染和心血管事件,并加强疾病进展监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms associated with an increased risk of progression to secondary acute myeloid leukemia (sAML). This study investigates the genomic correlates of disease progression in MDS by profiling active genomic regulatory regions and their transcriptional impact using H3K27ac chromatin immunoprecipitation-sequencing and RNA-sequencing analysis on CD34+ bone marrow progenitors cells isolated from a prospective cohort of 86 and 357 patients, respectively. Our analysis revealed distinct patterns of genomic region activation and transcriptional regulation across different disease stages such as low-risk MDS, high-risk MDS, and sAML. Unexpectedly, unsupervised clustering revealed a subset of patients with low-risk MDS displaying regulatory and transcriptional profiles similar to those of high-risk MDS and sAML, highlighting early molecular events that may predispose patients to disease progression. This subset is characterized by PU.1 genomic occupancy in regions linked to immune and inflammatory responses, increased T-cell and natural killer cell activation, and a higher frequency of SRSF2 mutations. Clinically, patients in this group exhibit greater susceptibility to infections and cardiovascular events, along with an elevated risk of disease progression, resulting in significantly reduced overall survival. Functional studies demonstrated that PU.1 inhibition suppresses MDS cell proliferation and clonogenicity, as impaired PU.1 binding inhibits the activation of key transcriptional programs involved in disease advancement. Collectively, these findings identify epigenetic factors that predispose patients with low-risk MDS to progression to high-risk MDS and, ultimately, sAML.
引用
- Vallelonga V, Gandolfi F, Zampini M, et al. PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression. Blood. 2026. PMID: 41538708. doi:10.1182/blood.2025030760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。